Department of Neurodegeneration, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
Mov Disord. 2012 Apr 15;27(5):656-65. doi: 10.1002/mds.24985.
It is currently widely acknowledged that the natural history of PD includes a preclinical phase, and there are increasing efforts to identify markers that would allow the identification of individuals at risk for PD. Here, we discuss the issues related to defining at-risk populations for PD and review findings of current population-based cohorts that have reported potential biomarkers for PD, such as the Honolulu-Asia Aging Study (HAAS) and the PRIPS (Prospective Validation of Risk factors for the development of Parkinson Syndromes) study. We also discuss enriched risk cohorts designed to evaluate specificity and predictive value of markers exemplified by the PARS (Parkinson Associated Risk Study) and the TREND (Tübinger evaluation of Risk factors for the Early detection of NeuroDegeneration) study. Although there is still a long way to go, studies designed according to these concepts might eventually provide sufficient data to form the basis for future screening programs for PD risk to be applied at a population level.
目前人们普遍认为 PD 的自然病程包括临床前期，并且越来越多的人正在努力寻找能够识别 PD 高危个体的标志物。在这里，我们讨论了定义 PD 高危人群的相关问题，并回顾了目前基于人群的队列研究报告的 PD 潜在生物标志物的结果，如 Honolulu-Asia Aging Study (HAAS) 和 PRIPS (Parkinson Syndromes 发展风险因素的前瞻性验证)研究。我们还讨论了专门设计的富集风险队列，以评估标志物的特异性和预测值，例如 PARS (Parkinson Associated Risk Study) 和 TREND (Tübinger 评估早期神经退行性变的风险因素)研究。尽管还有很长的路要走，但根据这些概念设计的研究最终可能会提供足够的数据，为未来在人群水平上进行 PD 风险筛查计划奠定基础。
